B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos - PubMed (original) (raw)

. 2000 Mar 30;19(14):1752-63.

doi: 10.1038/sj.onc.1203491.

Affiliations

• PMID: 10777209
• DOI: 10.1038/sj.onc.1203491

B-ATF functions as a negative regulator of AP-1 mediated transcription and blocks cellular transformation by Ras and Fos

D R Echlin et al. Oncogene. 2000.

Abstract

B-ATF is a nuclear basic leucine zipper protein that belongs to the AP-1/ATF superfamily of transcription factors. Northern blot analysis reveals that the human B-ATF gene is expressed most highly in hematopoietic tissues. Interaction studies in vitro and in vivo show that the leucine zipper of B-ATF mediates dimerization with members of the Jun family of proteins. Chimeric proteins consisting of portions of B-ATF and the DNA binding domain of the yeast activator GAL4 do not stimulate reporter gene expression in mammalian cells, indicating that B-ATF does not contain a conventional transcription activation domain. Jun/B-ATF dimers display similar DNA binding profiles as Jun/Fos dimers, with a bias toward binding TRE (12-O-tetradecanolyphorbol-13-acetate-response element) over CRE (cyclic AMP-response element) DNA sites. B-ATF inhibits transcriptional activation of a reporter gene containing TRE sites in a dose-dependent manner, presumably by competing with Fos for Jun and forming transcriptionally inert Jun/B-ATF heterodimers. Stable expression of B-ATF in C3H10T1/2 cells does not reduce cell viability, but does result in a reduced cellular growth rate when compared to controls. This effect is dominant in the presence of the growth promoting effects of the H-Ras or the v-Fos oncoproteins, since expression of B-ATF restricts the efficiency of focus formation by these transforming agents. These findings demonstrate that B-ATF is a tissue-specific transcription factor with the potential to function as a dominant-negative to AP-1.

PubMed Disclaimer

Similar articles

• Heterodimerization of c-Jun with ATF-2 and c-Fos is required for positive and negative regulation of the human urokinase enhancer.
  De Cesare D, Vallone D, Caracciolo A, Sassone-Corsi P, Nerlov C, Verde P. De Cesare D, et al. Oncogene. 1995 Jul 20;11(2):365-76. Oncogene. 1995. PMID: 7624151
• Jun and Fos heterodimerize with ATFa, a member of the ATF/CREB family and modulate its transcriptional activity.
  Chatton B, Bocco JL, Goetz J, Gaire M, Lutz Y, Kedinger C. Chatton B, et al. Oncogene. 1994 Feb;9(2):375-85. Oncogene. 1994. PMID: 8290251
• Distinct roles of Jun : Fos and Jun : ATF dimers in oncogenesis.
  van Dam H, Castellazzi M. van Dam H, et al. Oncogene. 2001 Apr 30;20(19):2453-64. doi: 10.1038/sj.onc.1204239. Oncogene. 2001. PMID: 11402340 Review.
• fos-jun Conspiracy: implications for the cell.
  Verma IM, Ransone LJ, Visvader J, Sassone-Corsi P, Lamph WW. Verma IM, et al. Princess Takamatsu Symp. 1989;20:119-26. Princess Takamatsu Symp. 1989. PMID: 2518685 Review.

Cited by

• Bach2-Batf interactions control Th2-type immune response by regulating the IL-4 amplification loop.
  Kuwahara M, Ise W, Ochi M, Suzuki J, Kometani K, Maruyama S, Izumoto M, Matsumoto A, Takemori N, Takemori A, Shinoda K, Nakayama T, Ohara O, Yasukawa M, Sawasaki T, Kurosaki T, Yamashita M. Kuwahara M, et al. Nat Commun. 2016 Sep 1;7:12596. doi: 10.1038/ncomms12596. Nat Commun. 2016. PMID: 27581382 Free PMC article.
• Transcriptional analysis of HIV-specific CD8+ T cells shows that PD-1 inhibits T cell function by upregulating BATF.
  Quigley M, Pereyra F, Nilsson B, Porichis F, Fonseca C, Eichbaum Q, Julg B, Jesneck JL, Brosnahan K, Imam S, Russell K, Toth I, Piechocka-Trocha A, Dolfi D, Angelosanto J, Crawford A, Shin H, Kwon DS, Zupkosky J, Francisco L, Freeman GJ, Wherry EJ, Kaufmann DE, Walker BD, Ebert B, Haining WN. Quigley M, et al. Nat Med. 2010 Oct;16(10):1147-51. doi: 10.1038/nm.2232. Epub 2010 Oct 3. Nat Med. 2010. PMID: 20890291 Free PMC article.
• Extra-telomeric functions of telomerase in the pathogenesis of Epstein-Barr virus-driven B-cell malignancies and potential therapeutic implications.
  Giunco S, Petrara MR, Zangrossi M, Celeghin A, De Rossi A. Giunco S, et al. Infect Agent Cancer. 2018 Apr 10;13:14. doi: 10.1186/s13027-018-0186-5. eCollection 2018. Infect Agent Cancer. 2018. PMID: 29643934 Free PMC article. Review.
• The AP-1 transcription factor Batf controls T(H)17 differentiation.
  Schraml BU, Hildner K, Ise W, Lee WL, Smith WA, Solomon B, Sahota G, Sim J, Mukasa R, Cemerski S, Hatton RD, Stormo GD, Weaver CT, Russell JH, Murphy TL, Murphy KM. Schraml BU, et al. Nature. 2009 Jul 16;460(7253):405-9. doi: 10.1038/nature08114. Epub 2009 Jul 5. Nature. 2009. PMID: 19578362 Free PMC article.
• The transcription factor BATF controls the global regulators of class-switch recombination in both B cells and T cells.
  Ise W, Kohyama M, Schraml BU, Zhang T, Schwer B, Basu U, Alt FW, Tang J, Oltz EM, Murphy TL, Murphy KM. Ise W, et al. Nat Immunol. 2011 Jun;12(6):536-43. doi: 10.1038/ni.2037. Epub 2011 May 15. Nat Immunol. 2011. PMID: 21572431 Free PMC article.

Publication types

MeSH terms

Substances

LinkOut - more resources

• Full Text Sources

  • Nature Publishing Group

• Other Literature Sources

  • The Lens - Patent Citations Database

• Molecular Biology Databases

  • BioCyc
  • GlyGen glycoinformatics resource

• Research Materials

  • NCI CPTC Antibody Characterization Program

• Miscellaneous

  • NCI CPTAC Assay Portal